This page is also available in:
Français
AstraZeneca is making big moves with its inhaler, Breztri Aerosphere, aiming to expand its use beyond chronic obstructive pulmonary disease (COPD) to also treat asthma. This could bring the company closer to its sales goal of $3 to $5 billion a year.
Breztri is a 3-in-1 inhaler that combines three drugs to help people breathe easier. It’s already approved for COPD and includes a steroid (budesonide), a bronchodilator (formoterol fumarate), and another medicine to open the airways (glycopyrronium). Now, AstraZeneca wants to prove that Breztri can also help people with uncontrolled asthma.
Two large studies, named KALOS and LOGOS, tested Breztri on over 4,400 patients with asthma. The results were promising—Breztri worked better than the usual two-drug treatments at improving lung function. This means patients could breathe more easily and have fewer symptoms like coughing or wheezing. AstraZeneca plans to share these findings with health regulators soon.
JoinAStudy.ca would like to congratulate Principal Investigator Dr Anil Gupta, whose efforts were crucial in gathering the data necessary to arrive at these conclusions. The study participants and coordinator team at his research site also deserve acknowledgment and thanks for providing their valuable time and effort.
If Breztri gets approved for asthma, it could help millions. Around 262 million people globally have asthma, and many don’t get full relief from current treatments. The expansion could also boost Breztri’s sales, which already hit $300 million in the first quarter of 2025—a 37% increase from last year.
Even though Breztri has lagged behind competitor GSK’s Trelegy Ellipta, which made $3.5 billion in 2024, AstraZeneca is confident in its inhaler’s future. It’s also working on other asthma drugs like Fasenra and Tezspire, both showing strong sales and growth.
Read more on this story by clicking here.
